Prophylactic indomethacin: systematic review and meta-analysis

Area of Science:

• Neonatal Medicine
• Pharmacology
• Clinical Trials

Background:

• Premature infants (<1750g) are at high risk for patent ductus arteriosus (PDA) and intraventricular hemorrhage (IVH).
• Prophylactic indomethacin is used to prevent these complications, but its overall effectiveness and safety profile require thorough evaluation.

Purpose of the Study:

• To assess the efficacy of prophylactic intravenous indomethacin in minimizing mortality and morbidity associated with PDA and IVH in low birth weight infants.
• To synthesize evidence from randomized controlled trials on the impact of prophylactic indomethacin.

Main Methods:

• Comprehensive literature search of Medline, Embase, and Oxford Database of Perinatal Trials (1980-present).
• Inclusion of 14 randomized controlled trials based on strict eligibility criteria.
• Independent assessment of study quality and data extraction by two observers.
• Meta-analysis techniques employed to pool results and estimate treatment effects.

Main Results:

• A trend towards reduced neonatal mortality was observed with prophylactic indomethacin.
• Significant reduction in symptomatic patent ductus arteriosus (PDA) incidence (RD -0.217, 95% CI -0.275 to -0.160).
• Significant reduction in grades 3 and 4 intraventricular hemorrhage (IVH) incidence (RD -0.039, 95% CI -0.066 to -0.011).
• No significant effect on respiratory outcomes.
• Potential transient impairment of renal function and a trend towards increased necrotizing enterocolitis noted.
• Insufficient data on long-term neurodevelopmental outcomes.

Conclusions:

• Prophylactic indomethacin offers immediate benefits in reducing PDA and IVH in high-risk infants.
• Further research is necessary to evaluate long-term adverse effects and neurodevelopmental outcomes.
• Routine recommendation for prophylactic indomethacin is pending comprehensive data on safety and long-term efficacy.